Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT06960447

Nd:YAG vs Alexandrite Laser Treatment in Hidradenitis Suppurativa

The purpose of this study is to evaluate whether Alexandrite laser treatment is non-inferior to Nd:YAG (neodymium-doped yttrium aluminum garnet) laser treatment of hidradenitis suppurativa (HS).

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Hidradenitis Suppurativa (HS) Bacterial Infections Bacterial Infections and Mycoses Hidradenitis Hidradenitis Suppurativa Infections Skin Diseases Skin Diseases, Bacterial Skin Diseases, Infectious Skin and Connective Tissue Diseases Suppuration Sweat Gland Diseases

Age range

12 year–75 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Geisinger male or female patients with a diagnosis of hidradenitis suppurativa (all stages of disease)
  • 12-75 years of age
  • Not on concurrent systemic therapy (e.g., antibiotics, biologic therapies)
  • Must have not used systemic therapies within 2 weeks of enrollment in study
  • Able and willing to provide consent

Exclusion criteria

  • Patients who cannot tolerate laser therapy
  • Patients who cannot wear protective eyewear
  • Patients who are pregnant

Treatment and study plan

Nd:Yag Laser

Device

Nd:YAG laser applied to one side of the participant's body (e.g. left or right) according to randomization, every 4-6 weeks for 4 consecutive treatments.

Alexandrite Laser

Device

Alexandrite laser applied to the contralateral side of the participant's body (e.g. left or right) according to randomization, every 4-6 weeks for 4 consecutive treatments.

Primary outcomes

  1. HiSCR50

    Time frame: 6 months

    Percentage of patients achieving a 50% reduction in their hidradenitis suppurativa clinical response (HiSCR) score.

  2. HiSQOL

    Time frame: 6 months

    The Hidradenitis Suppurativa Quality Of Life (HiSQOL) scale, a validated HS quality of life index and is comprised of a 17-item HS-specific HRQOL instrument with a 7-day recall period. Score ranges from 0 to 68, with higher scores indicating more severe impact

Secondary outcomes

  1. Pain VAS score

    Time frame: 6 months

    Visual analogue score for pain ranging from 0-10 with higher scores indicating worse pain.

  2. Pruritus numeric rating scale

    Time frame: 6 months

    As measured by a numeric rating scale from 0-10 with higher scores indicating worse itching.

  3. Days free of disease in last 30 days

    Time frame: 6 months

    The number of days a patient has not had a flare of HS in the past 30 days.

  4. AN Count

    Time frame: 6 months

    Number of abscesses and nodules on exam

Study contacts

Contact information is provided by the study sponsor or research team.

Saritha Research Project Manager

CONTACT

[email protected]

570-214-3453

Sponsors and collaborators

Lead sponsor

Geisinger Clinic

Other

Registry information

Official study title

Comparative Efficacy of Nd:YAG and Alexandrite Laser Treatments in Hidradenitis Suppurativa: A Split-Person, Non-Inferiority Study

Important dates

Study start
2026
Primary completion
2027
Study completion
2027
First posted
May 7, 2025
Registry last updated
Apr 28, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.